[Featured Stock] Celltrion Soars on Merger News with Pharmaceutical and Healthcare Companies

Chairman Seo Jung-jin Announces 'Merger 추진', Stocks Surge
CELLTRION Pharm Soars Near Upper Limit

[Asia Economy Reporter Minwoo Lee] The stock prices are soaring following the news of the merger plan among the three companies: Celltrion, Celltrion Healthcare, and Celltrion Pharm.

As of 2:47 PM today, Celltrion is trading at 180,000 KRW, up 1.98% compared to the previous day.

Its subsidiary, Celltrion Pharm, rose even more sharply. At the same time, it is trading at 46,000 KRW, up 20.89% from the previous day. At 1:49 PM today, it recorded 48,450 KRW, up 27.33% from the previous day, marking an all-time high. Celltrion Healthcare is also trading at 55,100 KRW, up 5.96% from the previous day.

This is interpreted as a result of Chairman Seo Jung-jin of Celltrion announcing his intention to pursue the merger of the three companies. Earlier, after his presentation at the JP Morgan Healthcare Conference held in San Francisco, USA, on the 15th (local time), Chairman Seo stated, "Celltrion is focused on biopharmaceuticals, Celltrion Healthcare on distribution, and Celltrion Pharm on chemically synthesized drugs," adding, "Around next year, we will ask shareholders whether they want the merger, and if shareholders agree, we will proceed accordingly."

This content was produced with the assistance of AI translation services.